Why is ziconotide given intrathecally?

Ziconotide does not cross the blood-brain barrier in therapeutic amounts and would require extremely high systemic doses to achieve spinal analgesia, causing severe side effects. Intrathecal delivery (directly into the cerebrospinal fluid via an implanted pump) allows precise targeting of spinal cord N-type calcium channels with minimal systemic exposure. This route is essential for both efficacy and safety.

Is ziconotide an opioid?

No. Ziconotide is not an opioid and does not interact with mu, kappa, or delta opioid receptors. It is a calcium channel blocker derived from cone snail venom. This means it has zero risk of respiratory depression, opioid-induced hyperalgesia, or addiction. However, it carries a black box warning for severe neuropsychiatric adverse effects (psychosis, hallucinations, paranoia) that require careful patient selection and monitoring.

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Ziconotide

AFDA Approved

Moderate Credibility

1 cited studyy · Evidence level A

N-type calcium channel blocker (omega-conopeptide) · 25 amino acids · Brand: Prialt

FDA ApprovedPrescription Required

Ziconotide is a synthetic peptide analog of omega-conotoxin MVIIA, derived from the venom of the cone snail Conus magus. It is the first non-opioid intrathecal analgesic approved by the FDA for severe chronic pain. It acts by blocking N-type calcium channels in the spinal cord, preventing neurotransmitter release from pain-signaling neurons.

Mechanism of Action

Selectively binds to N-type voltage-gated calcium channels (Cav2.2) on primary afferent nociceptive neurons in the dorsal horn of the spinal cord. This blocks calcium influx, preventing release of glutamate, substance P, and CGRP — key neurotransmitters in pain signaling. Unlike opioids, it does not activate mu-receptors and has no risk of respiratory depression or addiction.

Benefits

First non-opioid intrathecal analgesic for severe chronic pain^[1]
No risk of respiratory depression or opioid addiction
Effective for neuropathic and nociceptive pain refractory to other therapies^[1]
No development of tolerance with long-term use

Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Ziconotide — Dosing in Published Research

Reported Routes: Intrathecal infusion

Intrathecal infusion only, administered via implanted pump. Initial dose: 2.4 mcg/day (0.1 mcg/hour), titrated by ≤2.4 mcg/day at intervals of ≥2-3 weeks. Maximum recommended dose: 19.2 mcg/day (0.8 mcg/hour) or 17.1 mcg/day at 21 mcg/mL concentration. Requires specialized pain management center.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

Neuropsychiatric effects (confusion, hallucinations, paranoia, mood changes)
Dizziness, headache, somnolence
Nausea and vomiting
Gait abnormalities and nystagmus
Urinary retention
Risk of severe psychiatric adverse events (black box warning)

Ready to Discuss Ziconotide with a Doctor?

Ziconotide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Find a Prescribing Provider

Telehealth consultations available in most states

FDA ApprovedBoard-Certified DoctorsPrescription if Appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Approved Treatment Routing

Ziconotide in PeptideScholar's current approved-treatment dataset

Ziconotide is currently modeled on this site as an approved treatment path for: Management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments. Brand names in the current dataset: Prialt.

Validation Note

This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.

View treatment routing profiles Use provider matcher Review legal guidance

Research & Evidence

RCTJ Pain Symptom Manage, 2006

A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.

Intrathecal ziconotide significantly reduced pain scores vs placebo in patients with severe chronic pain refractory to conventional therapy

PMID: 16716870

References

1. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.. J Pain Symptom Manage, 2006. “Intrathecal ziconotide significantly reduced pain scores vs placebo in patients with severe chronic pain refractory to conventional therapy” [PMID: 16716870]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

GLP-1 Support Essentials

Products to help manage side effects and optimize outcomes during treatment.

LMNT Electrolyte Packets

Sodium-focused electrolytes to prevent dehydration and fatigue common in early GLP-1 therapy.

$30–45View on Amazon

High-Protein Shakes (30g)

Convenient protein shakes to maintain muscle mass on reduced GLP-1 caloric intake.

$28–42View on Amazon

Metamucil Fiber Supplement

Soluble fiber powder to manage constipation and GI side effects during GLP-1 treatment.

$20–30View on Amazon

Vitamin B12 (Methylcobalamin 1000mcg)

GLP-1 agonists can reduce B12 absorption over time — methylcobalamin is the most bioavailable form.

$10–20View on Amazon

Ginger Chews for Nausea

Natural nausea relief for the dose-escalation adjustment period, particularly weeks 1–4.

$8–15View on Amazon

Unflavored Whey Protein Isolate

Preserve lean mass without excess carbs or calories when appetite is suppressed.

$35–60View on Amazon

Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor weight, body composition, and nutrition to maximize results.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.

Ziconotide FAQ

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get peptide research updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.